Bladder (urinary) Tumor Cells
Bladder (urinary) tumors, most commonly urothelial carcinomas, arise from the epithelial lining of the urinary bladder and display marked heterogeneity in clinical behavior and molecular features. These malignancies range from non–muscle-invasive tumors with high recurrence rates to aggressive muscle-invasive disease associated with metastasis and poor prognosis.
Our bladder (urinary) tumor cell line collection provides well-defined in vitro models for investigating tumor initiation and progression, studying molecular mechanisms, and evaluating therapeutic strategies across different stages and subtypes of bladder cancer.
Reliable Authentic Diverse Supported
Key Features & Expertise
Our bladder (urinary) tumor cell lines are developed to support a wide range of research applications
Coverage Across Disease Stages and Subtypes
- Includes models of non–muscle-invasive and muscle-invasive bladder cancer
- Representation of urothelial carcinoma as well as variant histologies
- Supports studies on tumor progression, recurrence, and metastasis
Molecularly Relevant Models
- Characterized alterations in key genes such as FGFR3, TP53, RB1, and PIK3CA
- Reflect major signaling pathways involved in bladder tumorigenesis
- Applicable to targeted therapy and biomarker research
Reliable Quality and Reproducibility
- STR-authenticated to ensure identity and traceability
- Mycoplasma-free and quality-controlled before release
- Consistent growth characteristics for reproducible experiments
FAQ
What types of bladder tumor cell lines are included in this collection?
The collection primarily includes urothelial carcinoma cell lines, covering both non–muscle-invasive and muscle-invasive bladder cancer. Some models may also represent variant histologies or specific molecular subtypes relevant to research applications.
How do I select an appropriate bladder cancer cell model?
Model selection typically depends on your study objectives. Key factors include:
- Disease stage (non-invasive vs muscle-invasive)
- Genetic background (e.g., FGFR3 or TP53 status)
- Drug response characteristics
- Compatibility with specific experimental systems
Are the bladder tumor cell lines authenticated and quality controlled?
Yes. All cell lines are authenticated using STR profiling and tested to confirm they are free from mycoplasma contamination, ensuring reliability and consistency in downstream applications.
Can these cell lines be used for drug screening studies?
Yes, these models are widely used in drug discovery and screening workflows, including evaluation of chemotherapeutics, targeted agents, and combination therapies relevant to bladder cancer.
Do these models reflect the heterogeneity of bladder cancer?
While individual cell lines represent specific tumor characteristics, using a panel of models allows researchers to capture the diversity of bladder cancer in terms of molecular features and biological behavior.
Is molecular characterization data available for these cell lines?
For many cell lines, we provide relevant characterization data, including mutation profiles and pathway information, to support informed selection and experimental design.
What are the recommended storage and handling conditions?
Cell lines are typically supplied as cryopreserved vials or on dry ice. Upon arrival, they should be stored in liquid nitrogen for long-term preservation and handled using standard cell culture practices.